[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assiut University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":556},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1346,0,25,[9,39,57,75,90,114,136,159,181,201,224,250,269,298,330,351,372,397,420,443,469,490,505,519,537],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100652968","phase-4-effect-of-post-operative-low-dose-oral-azithromycin-in-chronic-rhinosinusitis-patients-with-nasal-polyps-100652968",false,"NCT07780292","Effect of Post Operative Low Dose Oral Azithromycin in Chronic Rhinosinusitis Patients With Nasal Polyps","Inclusion Criteria:\n\n* • Adult patients of both sexes aged ≥ 18 years.\n\n  * Documented clinical and radiological diagnosis of Chronic Rhinosinusitis with Nasal Polyps (CRSWNP).\n  * Patients with high baseline disease severity scores based on:\n* CT Paranasal Sinuses Staging: High Lund-Mackay CT Score.\n* Symptom Burden Assessment: High SNOT-22 Questionnaire Score. • Patients who comply with scheduled follow-up visits and appointments.\n\nExclusion Criteria:\n\n* • Patients aged under 18 years (\\\u003C 18 years).\n\n  * Presence of unilateral nasal polyps, antrochoanal polyps, granuloma \u002F granulomatous lesions, fungal\n  * rhinosinusitis, or suspected benign or malignant sinonasal neoplasms.\n  * Development of significant drug-related adverse effects, adverse reactions, or clinical complications during the\n  * treatment course.\n  * Known hypersensitivity or previous severe allergic reactions to macrolide antibiotics.\n  * Baseline prolonged QTc interval, active cardiac arrhythmias, or significant cardiovascular disease.\n  * Pre-existing significant impairment of hepatic or renal functions.\n  * Pregnant and lactating female patients.\n  * Patients who fail to adhere to follow-up visits or refuse to sign the informed consent.","ALL","18 Years",{"count":19,"type":20},52,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Chronic Rhinosinusitis with Nasal Polyps (CRSWNP) is a complex and persistent inflammatory disease of the paranasal sinus mucosa. It is clinically characterized by long-standing sinonasal mucosal inflammation, severe nasal congestion, continuous anterior and posterior rhinorrhea, facial pressure or fullness, and partial or complete loss of olfactory function. Functional Endoscopic Sinus Surgery (FESS) remains the primary surgical procedure of choice for CRSWNP cases that are refractory to conventional medical management. The ultimate goal of FESS is to restore surgical drainage pathways, improve sinus clearance, and re-establish proper sinus ventilation. This surgical intervention creates an anatomical environment optimal for post-operative topical medical therapies. Nevertheless, persistent mucosal inflammation, recalcitrant tissue edema, and post-operative recurrence of polypoid tissue represent major challenges during long-term follow-up. Despite initial surgical success, recurrent nasal polyposis remains a significant clinical challenge following Functional Endoscopic Sinus Surgery (FESS). In cases of recurrence, medical management plays a pivotal role in controlling mucosal inflammation and delaying or preventing re-operation. Diverse pharmacological interventions have been explored to control post-operative recurrence, including standard anti-inflammatory regimens as well as alternative systemic therapies such as some antibiotics, long-term macrolides, and novel biologics targeting specific inflammatory pathways. Macrolides, particularly 15-membered azalides such as Azithromycin, possess significant immunomodulatory and anti-inflammatory properties distinct from their classic antibacterial actions. When administered in low doses over extended periods, Azithromycin actively downregulates pro-inflammatory cytokines, inhibits tissue neutrophil infiltration, decreases goblet cell hypersecretion, and fosters mucosal healing and epithelial restoration.",[26],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)","NOT_YET_RECRUITING","2026-08-19",{"date":30,"type":31},"2026-08-21","ACTUAL",{"date":33,"type":20},"2026-10",{"date":35,"type":20},"2027-12",{"name":37,"class":38},"Assiut University","OTHER",{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100652967","phase-4-comparison-of-the-effectiveness-of-greater-occipital-nerve-and-supratrochlear-nerve-pulsed-radiofrequency-versus-botulinum-toxin-type-a-injection-in-chronic-migraine-100652967","NCT07780136","Comparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine","Inclusion Criteria:\n\n* • Age between 18 and 65 years, either sex.\n\n  * Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (headache occurring on ≥15 days\u002Fmonth for \\>3 months, with migrainous features on ≥8 days\u002Fmonth).\n  * Inadequate response, intolerance, or contraindication to at least one standard oral preventive medication (e.g., amitriptyline, propranolol, topiramate, flunarizine, valproate).\n  * Stable dose of any concurrent prophylactic medication for at least 4 weeks prior to enrolment, with no planned change during the study period.\n  * Willingness and ability to complete headache diaries and follow-up visits.\n\nExclusion Criteria:\n\n* • Other primary headache disorders (tension-type headache, cluster headache, hemicrania continua) as the predominant headache type.\n\n  * Secondary headache due to an identifiable structural, infectious, vascular, or neoplastic cause (confirmed or suspected by history\u002Fimaging).\n  * Prior botulinum toxin injection or radiofrequency procedure for headache within the last 6 months.\n  * Known hypersensitivity or allergy to botulinum toxin or to local anesthetics.\n  * Pregnancy or lactation.\n  * Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome).\n  * Medication overuse headache not resolved prior to enrolment.","65 Years",{"count":47,"type":20},70,[23],"Migraine is a common chronic neurovascular disorder ranked among the leading causes of disability worldwide, and its global burden has continued to rise over the past three decades, with prevalence increasing substantially between 1990 and 2021the global number of prevalent cases, incident cases, and DALYs for migraine increased by 58%, 42%, and 58% respectively from 1990 to 2021 (1). In 2021, migraine affected an estimated 1.2 billion people globally, and although tension-type headache was more prevalent, migraine caused greater disability (2). Chronic migraine, defined as headache occurring on 15 or more days per month for more than three months, with migrainous features on at least 8 days, represents a particularly disabling subtype that is frequently refractory to standard pharmacological prophylaxis (3). Pharmacologic treatment of chronic migraine often has limited efficacy, prompting growing interest in interventional and peripheral neuromodulatory approaches (4).\n\nOnabotulinumtoxinA is currently the only FDA-approved interventional prophylactic therapy for chronic migraine, with efficacy established by class-one evidence from the PREEMPT clinical program (5). Although onabotulinumtoxinA is traditionally known for inhibiting muscle contraction, its efficacy in chronic migraine is now attributed to inhibition of SNARE-mediated vesicle trafficking in sensory as well as motor nerve terminals (6). However, treatment with onabotulinumtoxinA, while effective, must be repeated every three months for sustained relief and can impose a significant financial burden on patients (7), which has driven exploration of alternative peripheral procedures targeting the same pericranial sensory nerve distribution.\n\nGreater occipital nerve block and PRF have shown efficacy in reducing migraine frequency, intensity, and duration, with pulsed radiofrequency treatment thought to reduce conduction in nociceptive fibers through a neuromodulatory, non-neurodestructive mechanism (8). Randomized data comparing GON block with GON-PRF found that VAS pain scores were significantly lower in the PRF group than the GON block group at six months follow-up (9), and longer-term cohort data have shown durable benefit of GON-targeted radiofrequency techniques over twelve months of follow-up (10). Beyond the occipital nerve, radiofrequency ablation of pericranial nerves including the supratrochlear and supraorbital nerves has emerged as a promising option for headache conditions refractory to pharmacologic treatment, with a favorable and largely self-limited side-effect profile (7). Case reports have further demonstrated good therapeutic response to PRF in patients whose chronic migraine remained refractory even after botulinum toxin injection (10).\n\nDespite this growing evidence base, direct head-to-head comparisons between combined GON-supratrochlear nerve PRF and onabotulinumtoxinA injection, the two leading peripheral interventional strategies covering the trigeminal and occipital sensory distribution, remain scarce. Given the cost, repeated dosing requirement, and resource burden associated with botulinum toxin therapy, and the emerging durability data for PRF, a direct comparative study is warranted to determine which modality offers superior and more sustained efficacy, better safety, and greater cost-effectiveness for patients with chronic migraine.",[51],"Chronic Migraine Headache",{"date":30,"type":31},{"date":33,"type":20},{"date":55,"type":20},"2026-12",{"name":37,"class":38},{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":16,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":74,"locationsCount":4},"100652871","diagnostic-accuracy-of-bedside-optic-nerve-sheath-diameter-ultrasonography-for-detecting-raised-intracranial-pressure-compared-with-brain-ct-findings-in-children-with-traumatic-brain-injury-100652871","NCT07780279","Diagnostic Accuracy of Bedside Optic Nerve Sheath Diameter Ultrasonography for Detecting Raised Intracranial Pressure Compared With Brain CT Findings in Children With Traumatic Brain Injury","Inclusion Criteria:\n\n* 1\\. Children aged 6-12 years. 2. Patients presenting within 24 hours of traumatic brain injury. 3. Patients undergoing brain CT based on emergency department and neurosurgical assessment.\n\n  4\\. Patients with traumatic brain injury of any severity, as assessed by the Paediatric Glasgow Coma Scale (PGCS).\n\n  5\\. Haemodynamically stable patients who can undergo ocular ultrasonography.\n\nExclusion Criteria:\n\n* 1\\. Orbital fractures, globe rupture, extensive periorbital oedema preventing right ONSD measurement.\n\n  2\\. Earlier intracranial surgery or ventriculoperitoneal shunt. 3. Known congenital or got neurological disorders associated with altered intracranial pressure (e.g., hydrocephalus or intracranial tumours).\n\n  4\\. Patients transferred after receiving osmotherapy before the initial ONSD measurement.","6 Years","12 Years",{"count":66,"type":20},100,"OBSERVATIONAL","Traumatic brain injury (TBI) is a major cause of morbidity and mortality among children globally, with an estimated incidence ranging from 47 to 280 cases per 100,000 children (1). The burden of pediatric traumatic brain injury (pTBI) in low- and middle-income countries (LMICs) is characterized, because most pTBI occurs in LMICs (2). TBIs can have both short- and long-term effects including impairment of physical, cognitive, or emotional functions (3). Advances in acute trauma care have decreased mortality rates (4). Elevated intracranial pressure (ICP) following TBI or stroke has been recognized as an important second insult that is strongly correlated with increased mortality. Therefore, an increase in ICP can cause a decrease in brain perfusion and may result in brain ischemia (5). Early detection of raised intracranial pressure (RICP) is considered a better strategy to prevent secondary brain insult (6). The gold standard for ICP measurement is invasive techniques (i.e., ventriculostomy and intraparenchymal microtransducers), associated with risks, such as infection and haemorrhage (7). Several methods for noninvasive measuring of elevated ICP have been proposed: radiologic methods including computed tomography and ophthalmological techniques (8). Some brain computed tomography (CT) findings, such as brain parenchymal swelling, midline shifting, and compressed basal cisterns, are traditionally used for the indirect measurement of raised ICP (9). Among non-invasive methods, the measurement of optic nerve sheath diameter (ONSD) has gained particular interest (7). The optic nerve sheath is continuous with the meninges of the central nervous system and is encased with the subarachnoid membrane. Cerebrospinal fluid (CSF), located in the subarachnoid space, accumulates in the optic nerve sheath, thereby widening its diameter in the setting of increased ICP and limited intracranial compliance (10). Ultrasound assessments of ONSD could be a better option because of the low cost and rapid bedside operation without the need for radiation exposure, especially for cases that are unstable and require real-time monitoring of ICP in an intensive care unit (11). Despite existing research, there remains a gap in evaluating the diagnostic accuracy of the ONSD measured via ultrasound for the prediction of increased ICP in pediatric patients (12). This study aims to assess the diagnostic accuracy of bedside optic nerve sheath diameter ultrasonography for detecting raised intracranial pressure in pediatric traumatic brain injury using brain CT findings as the reference standard.",[70],"Traumatic Brain Injury",{"date":30,"type":31},{"date":33,"type":20},{"date":35,"type":20},{"name":37,"class":38},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":89,"locationsCount":4},"100652859","creatinine-body-weight-ratio-as-a-predictor-of-hepatic-steatosis-in-patients-with-metabolic-syndrome-100652859","NCT07780253","Creatinine-Body Weight Ratio as a Predictor of Hepatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Adults aged ≥18 years. • Patients fulfilling criteria of metabolic syndrome\n\nMetabolic syndrome will be diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Presence of at least three of the following:\n\n1. Waist circumference:\n\n   * Men\\>102 cm\n   * Women\\>88 cm\n2. Triglycerides ≥150 mg\u002FdL or treatment for hypertriglyceridemia.\n3. HDL cholesterol:\n\n   * Men\\\u003C40 mg\u002FdL\n   * Women\\\u003C50 mg\u002FdL\n4. Blood pressure ≥130\u002F85 mmHg or current antihypertensive treatment.\n5. Fasting blood glucose ≥100 mg\u002FdL or treatment for diabetes mellitus. • Patients willing to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Chronic liver disease other than MASLD.\n\n  * Viral hepatitis B or C.\n  * Significant alcohol intake.\n  * Hepatotoxic drug use.\n  * Chronic kidney disease stage 4 or 5.\n  * Acute kidney injury.\n  * Malignancy.\n  * Pregnancy.\n  * Active infection or inflammatory disease",{"count":82,"type":20},96,"Metabolic syndrome is a major global health burden characterized by a clustering of metabolic abnormalities including central obesity, hypertension, dyslipidaemia, and impaired glucose metabolism. Recent modelling data indicated that the worldwide prevalence of metabolic syndrome doubled between 2000 and 2023, reaching approximately 31% among women and 26% among men, with an estimated 1.54 billion adults affected globally \\[1\\].\n\nIn the Middle East and North Africa region, the prevalence of metabolic syndrome-associated liver disease has been reported to reach nearly 40% in the general population \\[2\\].\n\nHepatic steatosis, now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) following the 2023 multi-society Delphi consensus statement, encompasses a spectrum of conditions ranging from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma \\[3\\]. The global prevalence of NAFLD\u002FMASLD has been estimated at approximately 32.4%, with a steadily increasing trend over the past two decades \\[4\\].\n\nGiven that early identification of hepatic steatosis may prevent progression to advanced liver disease, there is a clinical need for simple, inexpensive, and readily available screening biomarkers \\[5\\].\n\nSerum creatinine is traditionally used as a marker of renal function; however, because creatinine is generated as a metabolic end-product of skeletal muscle, its circulating concentration also reflects total body muscle mass. Adjusting serum creatinine for body weight yields the creatinine-to-body weight (Cr\u002FBW) ratio, which has been proposed as a simple surrogate marker of relative muscle mass and sarcopenic obesity \\[6\\].\n\nIn a landmark longitudinal cohort of 13,728 participants, participants in the lowest Cr\u002FBW quartile demonstrated a significantly higher cumulative incidence of NAFLD compared with the highest quartile, confirming Cr\u002FBW as an independent predictor of fatty liver disease \\[7\\].\n\nReduced skeletal muscle mass and sarcopenia are increasingly recognized as contributors to insulin resistance and metabolic dysfunction, both of which are central to the pathogenesis of MASLD \\[8\\]. A bidirectional relationship between the Cr\u002FBW ratio and NAFLD has been demonstrated in a longitudinal study of 9,662 participants followed for four years, suggesting that low muscle mass and hepatic steatosis may reinforce one another \\[9\\].\n\nFurthermore, a recent cross-sectional study of 1,492 participants found that the Cr\u002FBW ratio independently predicted the severity of hepatic steatosis as measured by controlled attenuation parameter, with a threshold of 1.01 identifying high-risk individuals \\[10\\].\n\nDespite this emerging evidence, published data on the predictive value of the Cr\u002FBW ratio for hepaticsteatosis specifically in patients with metabolic syndrome remain limited. Most existing studies were conducted in East Asian populations and focused on NAFLD without selecting for the metabolic syndrome phenotype. Therefore, this study aims to evaluate the predictive value of the Cr\u002FBW ratio for hepatic steatosis in patients with metabolic syndrome attending Assiut University Hospital.",[85],"Metabolic Syndrome (MetS)",{"date":30,"type":31},{"date":33,"type":20},{"date":35,"type":20},{"name":37,"class":38},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":97,"enrollmentInfo":98,"targetDuration":99,"studyType":67,"phases":4,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":4},"100652816","sii-and-siri-as-prognostic-biomarkers-in-lupus-nephritis-100652816","NCT07780045","SII and SIRI as Prognostic Biomarkers in Lupus Nephritis","Emerging Inflammatory Biomarkers (SII and SIRI) for Predicting Disease Activity, Renal Flares and Outcomes in Lupus Nephritis: A Prospective Observational Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of systemic lupus erythematosus according to the 2019 EULAR\u002FACR classification criteria\n* Confirmed lupus nephritis according to ISN\u002FRPS classification\n\nExclusion Criteria:\n\n* Active infection, sepsis, or other concurrent inflammatory or autoimmune conditions\n* Malignancy or hematologic disorders affecting blood cell counts\n* Pregnancy\n* Use of medications significantly affecting blood counts (such as recent chemotherapy or G-CSF)\n* Incomplete medical records or anticipated loss to follow-up","70 Years",{"count":66,"type":20},"12 Months","This prospective observational study aims to evaluate the prognostic utility of the Systemic Immune-Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) as novel inflammatory biomarkers for monitoring disease activity and predicting renal progression, flares, and outcomes in patients with lupus nephritis.",[102,103,104],"Lupus Nephritis","Systemic Lupus Erythematosus","Kidney Diseases",[106,107,108],"Systemic Immune-Inflammation Index SII","Systemic Inflammation Response Index SIRI","Lupus Nephritis Biomarkers",{"date":30,"type":31},{"date":28,"type":20},{"date":112,"type":20},"2027-10-19",{"name":37,"class":38},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100652707","short-segment-versus-long-segment-transpedicular-screw-fixation-in-the-correction-and-preservation-of-ao-type-b-thoracolumbar-fracture-alignment-a-comparative-study-100652707","NCT07777653","Short Segment Versus Long Segment Transpedicular Screw Fixation in the Correction and Preservation of AO-Type B Thoracolumbar Fracture Alignment: A Comparative Study","Short Segment Versus Long Segment Transpedicular Screw Fixation in the Correction and Preservation of AO-Type B Thoracolumbar Fracture Alignment: A Comparative Study. To Compare the Radiological, Clinical and Functional Outcomes of Short-segment Versus Long-segment Transpediclular Screw Fixation in Patients With Thoracolumbar Fractures AO-type B.","Inclusion Criteria:\n\n* Age 18-65 years\n* Acute traumatic thoracolumbar fracture (AO type B)\n* Single-level fracture\n* Neurologically intact patient (ASIA E)\n\nExclusion Criteria:\n\n* Pathological fractures (malignancy, infection, metabolic bone disease)\n* Significant neurological deficit (ASIA A-D)\n* Previous spinal surgery at or adjacent to the fracture level\n* 2 or more level fractures\n* Associated anterior column reconstruction requirement (corpectomy)\n* Polytrauma precluding early spinal surgery\n* Pregnancy\n* Performance of surgical decompression",{"count":122,"type":20},60,[124],"NA","To compare the radiological, clinical and functional outcomes of short-segment versus long-segment transpediclular screw fixation in patients with thoracolumbar fractures AO-type B.",[127],"Thoracolumbar Compression Fractures",{"date":129,"type":31},"2026-08-20",{"date":131,"type":20},"2026-09-01",{"date":133,"type":20},"2028-10-01",{"name":37,"class":38},1,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100652555","application-of-different-scores-in-predicting-outcomes-of-cirrhotic-patients-awaiting-liver-transplantation-100652555","NCT07777705","Application of Different Scores in Predicting Outcomes of Cirrhotic Patients Awaiting Liver Transplantation","transplant","Inclusion Criteria:\n\n* • All patients with liver cirrhosis (whatever the etiology) eligible for liver transplantation above the age of 18.\n\n  * Written informed consent provided.\n\nExclusion Criteria:\n\n* Old age (above 60 years old)\n* Acute liver cell failure without underlying cirrhosis\n* Absolute contraindications (e.g., uncontrolled sepsis, severe cardiopulmonary dysfunction, active malignancy).\n* Extra-MELD indications (e.g., hepatopulmonary syndrome, refractory ascites, cholestatic pruritus, hepatoblastoma). We restricted our cohort to patients listed for liver transplantation based on MELD-driven indications. This decision was made to reduce heterogeneity and ensure that eligibility determinations were primarily driven by MELD scores, thereby allowing us to isolate the relative contribution of frailty in the context of MELD-based allocation","60 Years",{"count":145,"type":20},153,"the goal of this observational study is to apply different scores 1. To assess Fatigue, Frailty, Liver Transplant Comorbidity Index and MELD 3.0 in patients with liver cirrhosis awaiting liver transplantation.\n\n2\\. To evaluate the predictive accuracy of these Scores for the short-term outcomes (early complications, recurrent hospitalization and 3-month mortality). 3. To determine whether using these Scores in the pre-transplant evaluation improves risk stratification compared to MELD score alone.",[148,149],"Liver Cirrhosis","Liver Transplant",[151,152,153],"cirrhosis and transplantation","Liver cirrhosis","Liver transplantation",{"date":129,"type":31},{"date":131,"type":20},{"date":157,"type":20},"2028-01-01",{"name":37,"class":38},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":166,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100652844","tension-type-headache-and-its-association-100652844","NCT07779655","Tension-type Headache and Its Association","Tension-type Headache and Its Association With Smartphone Use,Sleep Quality and Quality of Life","Inclusion Criteria:\n\n* Adults aged 18-60 years\n* Attending the outpatient clinics at Assiut University Hospitals during the study period\n* Able to understand the study questionnaires and provide informed consent\n* No severe psychiatric illness or cognitive impairment interfering with questionnaire completion\n* No serious medical illness that may affect participation\n\nExclusion Criteria:\n\n* History of major neurological diseases (e.g., stroke, epilepsy, brain tumors)\n* History of secondary headache disorders\n* History of migraine or other primary headache disorders according to ICHD-3 criteria\n* Refusal to participate",{"count":167,"type":20},199,"To estimate the prevalence of tension-type headache among adults attending the outpatient clinics at Assiut University Hospitals, and to assess its association with smartphone use, sleep quality, and quality of life.",[170,171,172,173],"Tension-Type Headache","Sleep Disturbance","Smartphone Addiction","Quality of Life","2026-08-18",{"date":30,"type":31},{"date":177,"type":20},"2026-08-10",{"date":179,"type":20},"2028-08-10",{"name":37,"class":38},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100652803","comparison-between-radiofrequencyhydrodissection-and-cryoneurolysis-in-chronic-ankle-pain-100652803","NCT07778589","Comparison Between Radiofrequency,Hydrodissection and Cryoneurolysis in Chronic Ankle Pain","Analgesic Efficacy of Radiofrequency Versus Hydrodissection or Cryoneurolysis of the Superficial Peroneal Nerve in Chronic Ankle Pain Following Anterior Talofibular Ligament Injury in Athletes: A Randomized Comparative Trial","Inclusion Criteria:\n\n* Athletes aged 18-45 years\n* Chronic ankle pain (\\>6 months) following ATFL injury\n* Clinical and imaging confirmation of ATFL injury\n* No surgical indication (complete tear, associated fracture)\n* Failure of conservative treatment\n\nExclusion Criteria:\n\n* Previous ankle surgery\n* Peripheral neuropathy or systemic neurological disease\n* Contraindications to botulinum toxin, RF ablation, or cryoneurolysis\n* General exclusion criteria for intervention (local infection, coagulopathy, patient refusal)\n* long standing condition \\>5 y","45 Years",{"count":190,"type":20},87,[124],"Ligamentous injuries of the ankle are common among athletes. Inversion injuries of the ankle account for 40% of all athletic injuries. The anterior talofibular ligament (ATFL) and the calcaneofibular ligament (CFL) are sequentially the most commonly injured ligaments when a plantar-flexed foot is forcefully inverted. The posterior talofibular ligament (PTFL) is rarely injured, except in association with a complete dislocation of the talus.\n\nEighty percent of patients with lateral ankle injuries make a full recovery following conservative rehabilitation.\n\nUp to 20% of patients with an acute inversion injury develop chronic functional instability. Electromyography (EMG) has demonstrated prolonged reaction times of the peroneal muscle in this group of patients. Strengthening and proprioception exercises can lead to improvement. Patients whose injury does not respond and who have continued mechanical laxity and functional instability may be candidates for lateral ligament reconstruction Chronic pain of the lower extremity remains challenging to manage.Non-Surgical Treatments include\n\n* Physical therapy: Do strength, flexibility, and balance exercises to build support around the joint.\n* Bracing and support: Wear an ankle brace or use custom shoe inserts (orthotics) to stabilize your foot.\n* Activity changes: Swap high-impact sports like running for low-impact options like swimming or cycling.\n* Medications: Take nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to manage swelling and pain.\n* Injections: Get targeted corticosteroid or regenerative injections if recommended by a doctor.\n* Neuromodulaion : RFA, Cryneurolysis, botulinum injection Hydrodissection with botulinum toxin Hydrodissection is a minimally-invasive procedure that involves injecting fluid into anatomic spaces to facilitate dissection and adhesiolysis during surgery as proposed by Graesser et al. in 2022. In the past decade, it has been applied to the management of nerve entrapments by injecting fluid around the nerve to create space and separate them from surrounding structures. Injectates used are either saline, corticosteroids, anesthetic,dextrose water, platelet-rich plasma,Botulinum or combinations of these injectates Radiofrequency ablation in chronic ankle pain The use of both PRF and CRF has been reported to be used for chronic ankle and foot pain.CRF works by applying an active electrode to heat-targeted neural tissue to temperatures of 60-80 °C. These high temperatures cause coagulative necrosis, collagen destruction, and axonal degeneration, thereby resulting in third- and fourth-degree peripheral nerve injury . Pain relief is limited however by progressive axonal regeneration . In contrast to CRF, PRF delivers high-frequency current in a pulsed manner, allowing time between pulses for the dissipation of produced heat. As such, the electrode tip is kept at a maximum of 42 °C, which is below the temperature that produces nerve damage. Instead, though it is not yet clarified, it is thought that PRF employs a strong electromagnetic field to functionally change neuronal cells in small unmyelinated and lightly myelinated nerve fibers selectively. This in effect causes disruption of neuronal membranes, modulation of neuronal gene expression, and modulation of neuronal local cytokine release .\n\nFollowing treatment, immediate changes of endoneurial edema can be seen histologically and clinical pain relief may last several years Cryoneurolysis Cryoneurolysis, also known as cryoablation or cryoneuroablation, is the application of cold temperatures to targeted nerves to \"freeze\" them in an attempt to block pain signals . This technique was introduced to treat acute pain initially but has significantly gained interest as an intervention for those struggling with chronic pain conditions, primarily due to the failure of traditional interventions that resulted in temporary results and further complications. Evidence has shown that cryoneurolysis may offer long-term pain relief without the need for constant pharmaceutical interventions . It is for this reason that it represents a desirable therapeutic opportunity to consider for patients suffering from chronic knee pain, neuropathic pain, and post-surgery-related pain Owing to its minimally invasive\u002Fnon-invasive nature and lasting pain relief over months, cryoneurolysis offers significant advantages over traditional pain management methods . Furthermore, cryoneurolysis does not have systemic effects or addiction risks, as seen in long-term opioid use, making it a better pain management option today in the context of the increasing opioid crisis\n\nAim of study:\n\nTo evaluate and compare the efficacy of three ultrasound-guided neuromodulation techniques-hydrodissection with botulinum toxin, conventional radiofrequency ablation (RFA), and cryoneurolysis-targeting the superficial fibular nerve (SFN) in athletes with chronic ankle pain after anterior talofibular ligament (ATFL) injuries.",[194],"Chronic Ankle Pain in Athletes",{"date":30,"type":31},{"date":197,"type":20},"2026-10-20",{"date":199,"type":20},"2029-12-20",{"name":37,"class":38},{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":135},"100642464","smoking-cessation-counseling-performance-among-medical-interns-100642464","NCT07650721","Smoking Cessation Counseling Performance Among Medical Interns","Effect of Artificial Intelligence-Assisted Interactive Case-Based Training on Smoking Cessation Counseling Performance Among Medical Interns","Inclusion Criteria:\n\n* Medical interns enrolled in the internship training program at the Faculty of Medicine, Assiut University during the study period.\n* Able to attend the training session and complete all study assessments, including the pre-test and post-test evaluations.\n\nExclusion Criteria:\n\n* Previous formal structured training in smoking cessation counseling based on the 5A model.\n* Previous participation in a smoking cessation counseling educational program within the preceding 12 months.\n* Failure to complete the assigned educational intervention.\n* Failure to complete either the pre-test or post-test assessment.\n* Withdrawal of consent at any stage of the study.",{"count":209,"type":20},140,[124],"Smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is strongly associated with chronic respiratory diseases, cardiovascular disease, cancer, and premature death. Physicians play a central role in tobacco control through the delivery of smoking cessation counseling, and even brief physician advice has been shown to significantly increase smoking quit rates. The evidence-based 5A's model (Ask, Advise, Assess, Assist, and Arrange) is widely recommended as the standard framework for smoking cessation counseling.",[213],"Smoking Cessation",[213,215,216],"Artificial Intelligence","Medical Interns","RECRUITING",{"date":28,"type":31},{"date":220,"type":31},"2026-06-30",{"date":222,"type":20},"2026-10-01",{"name":37,"class":38},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":231,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100652427","serum-srage-cc16-and-syndecan-1-as-predictors-of-ards-and-mortality-after-severe-chest-trauma-100652427","NCT07774338","Serum sRAGE, CC16, and Syndecan-1 as Predictors of ARDS and Mortality After Severe Chest Trauma","Early Admission Serum Soluble Receptor for Advanced Glycation End Products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 as Independent Predictors of Acute Respiratory Distress Syndrome and In-Hospital Mortality Following Severe Isolated Chest Trauma: A Prospective Cohort Study.","Inclusion Criteria:\n\n* Adult patients aged 18 - 60 years old.\n\n  * Patients with blunt or penetrating severe chest trauma.\n  * Chest Abbreviated Injury Scale (Chest AIS ≥3).\n  * Admission within 24 hours of injury.\n  * Patients admitted to the Trauma Unit or Trauma ICU.\n  * Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* h. Age below 18 years or above 60 years old (to ensure a homogeneous adult study population and avoid age- related physiological differences).\n\n  * i. Hospital admission more than 24 hours after injury (to ensure early biomarker measurement before secondary inflammatory changes occur).\n  * j. Previous diagnosis of acute respiratory distress syndrome before admission (to ensure that ARDS outcomes are attributable to the index chest trauma).\n  * k. Pre-existing chronic interstitial lung disease (to avoid baseline pulmonary abnormalities that may influence biomarker levels and respiratory outcomes).\n  * l. Acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization (to minimize confounding from pre-existing acute pulmonary inflammation).\n  * m. Active pulmonary infection before trauma (to exclude pre-existing pulmonary inflammation that may alter biomarker levels and increase the risk of ARDS independently of trauma).\n  * n. End-stage chronic liver disease (to avoid altered inflammatory responses and poor clinical outcomes unrelated to chest trauma).\n  * o. End-stage renal disease requiring dialysis (to avoid altered clearance of circulating biomarkers and independently increased mortality risk).\n  * p. Active malignancy receiving chemotherapy or radiotherapy (to exclude patients with cancer-related systemic inflammation and immunosuppression that may affect biomarker levels and outcomes).\n  * q. Pregnancy (because physiological changes during pregnancy may influence biomarker levels and respiratory function).\n  * r. Patients transferred from another hospital more than 24 hours after injury (to ensure standardized early clinical assessment and biomarker sampling within the predefined study period).\n  * s. Refusal to participate in the study (because informed consent is required for study enrollment).\n  * t. Connective tissue diseases\n  * u. Severe burns and major inhalational injury v. Immunosuppressive therapy\n  * w. Chronic systemic inflammatory diseases\n  * x. Severe obesity ( BMI\\>40), if relevant.\n  * y. Poly trauma with AIS\\> or = 3 outside the chest.",{"count":232,"type":20},85,"This prospective cohort study aims to evaluate whether blood levels of soluble receptor for advanced glycation end products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 measured early after severe chest trauma can predict the development of acute respiratory distress syndrome (ARDS) and in-hospital mortality. Adult patients aged 18 years or older admitted with severe blunt or penetrating chest trauma will be enrolled. Clinical data, injury severity, laboratory findings, imaging results, and clinical outcomes will be recorded. Patients will be followed daily during the first 7 days after admission for the development of ARDS, and in-hospital mortality will be recorded until discharge or death. The findings may help identify patients at high risk of respiratory complications and poor outcomes after severe chest trauma.",[235,236],"Acute Respiratory Distress Syndrome","Chest Trauma",[238,239,240,241,242,243],"Severe chest trauma","Acute respiratory distress syndrome","sRANGE","CC16","Syndecan-1","Trauma biomarker","2026-08-17",{"date":28,"type":31},{"date":33,"type":20},{"date":248,"type":20},"2028-12",{"name":37,"class":38},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":266,"leadSponsor":268,"locationsCount":4},"100652306","atherosclerosis-in-early-rheumatoid-arthritis-patients-using-atherogenic-index-of-the-plasma-and-carotid-intima-media-thickness-100652306","NCT07772466","Atherosclerosis in Early Rheumatoid Arthritis Patients Using Atherogenic Index of the Plasma and Carotid Intima Media Thickness","Atherogenic Index of Plasma and Carotid Intima-media Thickness as Predictors of Preclinical Atherosclerosis in Early Rheumatoid Arthritis Patients Younger Than 50 Years of Age","Inclusion Criteria:\n\nfor cases (Rheumatoid Arthritis patients)\n\n* Patients fulfilling the 2010 American College of Rheumatology \u002F European League Against Rheumatism (ACR\u002FEULAR) classification criteria for RA\n* Disease duration of ≤6 months from the onset of symptoms (early RA)\n\nFor Controls (Healthy Subjects):\n\n* Healthy volunteers aged 18 to 49 years with no known inflammatory, autoimmune, or chronic disease.\n* Age- and sex-matched (within ±2 years) to case subjects\n\nExclusion Criteria:\n\n* Established cardiovascular disease (coronary artery disease, prior myocardial infarction, stroke, peripheral arterial disease, or heart failure).\n* Diabetes mellitus, Hypertension, and Dyslipidaemia on lipid-lowering therapy (statins, fibrates, niacin, or omega-3 agents), as these agents directly modify AIP values.\n* Chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²) and Hepatic disease, thyroid dysfunction, or any other significant endocrine disorder.\n* Pregnancy or lactation.\n* Other connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome).\n* Other inflammatory arthropathies (psoriatic arthritis, ankylosing spondylitis, reactive arthritis).","50 Years",{"count":47,"type":20},"Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting the peripheral joints, yet its extra-articular burden particularly on the cardiovascular (CV) system has emerged as its most consequential long-term complication . Cardiovascular disease (CVD) accounts for 40% of all deaths in RA patients, making it the leading cause of mortality .This excess CV risk is estimated to be 1.5 to 2 times higher than in the general population .The overall CV risk conferred by RA has been linked in magnitude to that of diabetes mellitus, underscoring RA as an independent cardiovascular risk factor formally recognised in the 2021 European Society of Cardiology Guidelines on CVD prevention .\n\nIn this context, the non-invasive detection of preclinical atherosclerosis before the onset of clinical CV events has become clinical priority. Carotid intima-media thickness (CIMT), measured by high-resolution B-mode ultrasonography, is a well-validated surrogate marker of early structural arterial wall changes that independently predicts future myocardial infarction and stroke .Multiple studies have documented significantly elevated CIMT in RA patients compared with age- and sex-matched controls; studies found higher CIMT values across all age groups in RA, with values increasing in proportion to disease severity as assessed by the Disease Activity Score in 28 joints .\n\nThe atherogenic index of plasma (AIP) defined as the base-10 logarithm of the triglyceride-to-HDL-cholesterol ratio has emerged as a calculated composite biomarker reflecting lipoprotein particle atherogenicity, particularly the preponderance of small, dense LDL particles .A high AIP (\\>0.21) has been independently associated with major adverse cardiovascular events beyond the predictive capacity of conventional lipid panels .",[261,262],"Atheroscleroses","Rheumatoid Arthritis (RA","2026-08-16",{"date":28,"type":31},{"date":222,"type":20},{"date":267,"type":20},"2028-12-30",{"name":37,"class":38},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":4},"100652460","ultrasound-assessment-of-internal-jugular-vein-for-cannulation-and-venous-pressure-prediction-100652460","NCT07773506","Ultrasound Assessment of Internal Jugular Vein for Cannulation and Venous Pressure Prediction","Ultrasound Guidance for Internal Jugular Vein Cannulation: Can Doppler Ultrasound Predict Jugular Venous Pressure Changes by Assessment of Internal Jugular Vein Diameter and Collapsibility?","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Patients admitted to the Intensive Care Unit (ICU), Emergency Department, or Operating Theatres who require internal jugular vein (IJV) cannulation for clinical indications.\n* Patients in whom ultrasound-guided right internal jugular vein cannulation is planned.\n* Patients who are hemodynamically stable enough to undergo ultrasound examination before cannulation.\n* Patients able to undergo vascular ultrasound examination in the supine position (0-30° head elevation according to the study protocol).\n* Patients in whom complete ultrasound assessment of the internal jugular vein can be performed (including maximum diameter, minimum diameter, cross-sectional area, and collapsibility\u002Fdistensibility index).\n* Patients with a clinically indicated assessment of central venous pressure (CVP) or jugular venous pressure (JVP) allowing comparison with ultrasound measurements.\n* Patients providing written informed consent, or consent obtained from a legally authorized representative when applicable.\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age.\n* Previous surgery, radiotherapy, or significant trauma involving the neck.\n* Known thrombosis, stenosis, or congenital anomalies of the internal jugular vein.\n* Local infection, cellulitis, burn, or hematoma at the intended cannulation site.\n* Large neck masses, thyroid enlargement, or cervical pathology causing distortion of neck anatomy.\n* Severe coagulopathy or uncontrolled bleeding disorders contraindicating internal jugular vein cannulation.\n* Patients with cervical spine instability or those in whom proper positioning for ultrasound examination is not possible.\n* Inadequate ultrasound visualization of the internal jugular vein.\n* Severe tricuspid valve disease or conditions causing marked alterations in central venous hemodynamics that interfere with accurate interpretation of IJV measurements.\n* Refusal of the patient or legally authorized representative to provide informed consent.",{"count":66,"type":20},"This prospective observational study aims to evaluate the diagnostic utility of vascular ultrasound for internal jugular vein (IJV) assessment in adult patients undergoing clinically indicated IJV cannulation.\n\nTraditionally, bedside clinical assessment of jugular venous pressure (JVP) is challenging and frequently imprecise in critically ill or obese individuals. This study investigates whether non-invasive ultrasound parameters, specifically IJV diameter, collapsibility index, and Doppler flow patterns, can reliably estimate central venous pressure (CVP) and identify elevated JVP.\n\nParticipants admitted to the Intensive Care Unit, Emergency Department, or Operating Theatres who require right IJV catheterization will receive a standardized pre-procedural vascular ultrasound evaluation in a supine position (0-30° head elevation) prior to routine, ultrasound-guided cannulation. Ultrasound measurements will then be compared to direct central venous pressure readings to assess diagnostic accuracy and correlation.",[279,280,281],"Vascular Access","Elevated Jugular Venous Pressure","Hemodynamic Instability",[283,284,285,286,287,288,289,290],"Internal Jugular Vein","Vascular Ultrasound","Ultrasound Guidance","Central Venous Catheterization","Jugular Venous Pressure","Central Venous Pressure","Collapsibility Index","Doppler Flow","2026-08-15",{"date":28,"type":31},{"date":294,"type":20},"2026-09",{"date":296,"type":20},"2027-10",{"name":37,"class":38},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":308,"conditions":309,"keywords":314,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":329,"locationsCount":4},"100652321","systemic-immune-inflammation-index-and-platelet-parameters-in-diabetic-kidney-disease-100652321","NCT07773467","Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease","Systemic Immune Inflammation Index With Related Blood Ratios and Platelet Parameters in Patients With Type 2 Diabetes Mellitus and Nephropathy","Inclusion Criteria:\n\n* Adults aged 18 to 80 years, both males and females.\n* Confirmed clinical diagnosis and history of Type 2 Diabetes Mellitus (T2DM).\n* Healthy control subjects matched for age and sex (for the control cohort).\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Acute infections or clinical signs of active inflammation at the time of sampling.\n* Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n* Known or recently diagnosed malignancies.\n* Chronic liver diseases, including cirrhosis or hepatitis.\n* Nephrotic syndrome or other known non-diabetic kidney diseases.\n* History of immunosuppressive therapy, systemic corticosteroids, or cytotoxic medications within the past 3 months prior to enrollment.\n* Pregnancy.\n* Significant cardiovascular complications.","80 Years",{"count":307,"type":20},120,"Diabetic kidney disease (DKD) is a frequent microvascular complication in individuals with type 2 diabetes mellitus (T2DM) and a major cause of chronic kidney failure worldwide. Chronic low-grade inflammation and platelet activation contribute significantly to renal microvascular damage.\n\nThe purpose of this observational study is to evaluate whether routine blood test markers, specifically the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet indices (such as mean platelet volume \\[MPV\\] and platelet distribution width \\[PDW\\]), can serve as simple, accessible, and cost-effective biomarkers for identifying the presence and progression of diabetic kidney disease.\n\nParticipants will include adult patients with type 2 diabetes categorized according to their urinary albumin-to-creatinine ratio (normoalbuminuria, microalbuminuria, and macroalbuminuria) as well as healthy control subjects. Complete blood counts, derived inflammatory indices, and renal parameters will be measured to assess their diagnostic accuracy for DKD.",[310,311,312,313],"Diabetic Kidney Disease","Diabetic Nephropathies","Type 2 Diabetes Mellitus","Albuminuria",[315,316,317,318,319,320,321,322,323,324,325],"Systemic Immune-Inflammation Index","SII","Neutrophil-to-Lymphocyte Ratio","NLR","Platelet-to-Lymphocyte Ratio","PLR","Mean Platelet Volume","MPV","Platelet Parameters","Platelet Distribution Width","Inflammatory Biomarkers",{"date":28,"type":31},{"date":294,"type":20},{"date":296,"type":20},{"name":37,"class":38},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":4},"100651528","the-effect-of-hydration-on-the-prevention-of-ci-aki-in-stemi-patients-undergoing-primary-pci-hydro-aki-trial-100651528","NCT07761754","The Effect of Hydration on the Prevention of CI-AKI in STEMI Patients Undergoing Primary PCI (Hydro-AKI Trial)","The Effect of Hydration on the Prevention of Contrast Induced Acute Kidney Injury (CI-AKI) in ST Segment Elevation Myocardial Infarction Undergoing Primary PCI (Hydro-AKI Trial)","Hydro-AKI","Inclusion Criteria:\n\nInclusion Criteria\n\nAll of the following must be present:\n\n* Age ≥18 years at the time of randomization\n* Clinical diagnosis of STEMI, confirmed by 12-lead ECG showing ≥30 minutes of ST-segment elevation ≥1 mm in ≥2 contiguous limb leads or ≥2 mm in ≥2 contiguous precordial leads, or new left bundle branch block with a clinical presentation consistent with acute myocardial infarction\n* Decision to proceed with primary PCI as the reperfusion strategy, within 12 hours of symptom onset (or up to 24 hours if evidence of persistent ischaemia or haemodynamic instability)\n* Estimated glomerular filtration rate (eGFR) ≥30 mL\u002Fmin\u002F1.73m², calculated by the CKD-EPI 2021 formula from the most recent available serum creatinine measurement prior to contrast exposure\n* Ability to swallow and safely tolerate oral fluids, as assessed by the attending physician\n* Oral informed consent obtained from the patient or a legally authorized representative (deferred consent protocol applies in emergencies per IRB approval)\n\nExclusion Criteria:\n\n* \\- Cardiogenic shock on presentation, defined as systolic blood pressure \\\u003C90 mmHg for \\>30 minutes despite fluid resuscitation, or requirement for vasopressor or inotropic therapy to maintain SBP ≥90 mmHg, with evidence of end-organ hypoperfusion (Killip Class IV)\n* Acute pulmonary oedema or Killip Class III with SpO₂ \\\u003C90% on room air, bilateral crepitations \\>50% of lung fields, or chest X-ray showing pulmonary venous congestion requiring urgent diuresis\n* Pre-existing dialysis dependence (haemodialysis or peritoneal dialysis) or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² on admission\n* Active vomiting, dysphagia, altered consciousness (GCS \\\u003C14), or any clinical condition precluding safe oral fluid intake, as assessed by the attending physician\n* Administration of any IV hydration protocol for CIN prevention prior to randomization (patients may have received standard IV fluids for other indications; these are documented but do not constitute exclusion unless specifically intended as CIN prophylaxis)\n* Known severe allergy to iodinated contrast media that cannot be managed with pre-medication (moderate\u002Fmild allergies and prior mild reactions are not exclusions)\n* Concurrent administration of known nephrotoxic agents within 48 hours that cannot be withheld or dose-adjusted: aminoglycoside antibiotics (gentamicin, amikacin), high-dose loop diuretics in the context of diuretic nephropathy, or cisplatin-based chemotherapy\n* Pregnancy (confirmed by urine or serum beta-hCG) or active breastfeeding\n* Estimated life expectancy \\\u003C30 days from a non-cardiac cause (advanced malignancy, end-stage liver disease, multiorgan failure)",{"count":339,"type":20},384,[124],"The goal of this clinical trial is to determine whether a structured oral hydration regimen reduces the incidence of contrast-induced acute kidney injury (CI-AKI) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). The main questions it aims to answer are:\n\nDoes a structured oral hydration regimen reduce the incidence of CI-AKI compared with standard care without a prescribed hydration regimen? Does oral hydration improve renal outcomes without increasing the risk of adverse events, such as heart failure or fluid overload, in patients undergoing PPCI?\n\nResearchers will compare patients receiving a structured oral hydration regimen with patients receiving standard care without a prescribed hydration regimen to determine whether oral hydration decreases the incidence of CI-AKI and improves clinical outcomes.\n\nParticipants will:\n\nBe randomly assigned to either the oral hydration group or the standard care group.\n\nUndergo primary percutaneous coronary intervention according to institutional practice.\n\nReceive the assigned hydration strategy after the procedure. Have serum creatinine measured at baseline and after contrast exposure to assess for CI-AKI.\n\nBe monitored for adverse events, including fluid overload, heart failure, need for renal replacement therapy, length of hospital stay, and other relevant clinical outcomes.",[343,344],"Contrast-Induced Acute Kidney Injury in ST-Segment Elevation Myocardial Infarction","Contrast Induced AKI",{"date":174,"type":31},{"date":347,"type":20},"2026-08",{"date":349,"type":20},"2029-06",{"name":37,"class":38},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":360,"conditions":361,"keywords":364,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":371,"locationsCount":4},"100652502","prevalence-of-fibromyalgia-in-patients-with-plaque-psoriasis-100652502","NCT07773766","Prevalence of Fibromyalgia in Patients With Plaque Psoriasis","Fibromyalgia in Patients With Plaque Psoriasis - Assiut University Hospital","Inclusion Criteria:\n\n* Adult patients (≥18 years) with clinically diagnosed plaque psoriasis.\n* Both males and females.\n* Willing to participate and provide written informed consent.\n* For controls: Apparently healthy age- and sex-matched volunteers.\n* For controls: No history of psoriasis, psoriatic arthritis, or other chronic inflammatory or rheumatic diseases.\n* For controls: Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with psoriatic arthritis or other inflammatory arthritis.\n* Patients with other diagnosed rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis).\n* Patients with previously diagnosed major depressive disorder or generalized anxiety disorder.\n* Patients with uncontrolled diabetes mellitus, heart failure, renal failure, or thyroid disorders.\n* Current use of antidepressants, anticonvulsants, or benzodiazepines.\n* History of malignancy.\n* Pregnancy.",{"count":359,"type":20},110,"This observational study aims to determine how common fibromyalgia syndrome and central sensitization are in adults with plaque psoriasis compared to healthy individuals. Plaque psoriasis is a chronic inflammatory skin disease that can affect the entire body, which may increase the risk of developing chronic pain conditions. Fibromyalgia causes widespread musculoskeletal pain, fatigue, and sleep disturbances, while central sensitization involves the central nervous system becoming highly sensitive to pain.\n\nResearchers will evaluate 55 adult patients diagnosed with plaque psoriasis and 55 age- and sex-matched healthy volunteers at the Dermatology Outpatient Clinic at Assiut University Hospital. Participants will undergo a clinical examination to assess their psoriasis severity and will complete standardized questionnaires to evaluate pain intensity, fibromyalgia symptoms, central sensitization, and overall quality of life. The findings of this study may help doctors better understand these overlapping conditions to improve the early identification and management of pain in patients with psoriasis.",[362,363],"Plaque Psoriasis","Fibromyalgia",[362,363,365,173,366],"Central Sensitization","Chronic Pain","2026-08-14",{"date":28,"type":31},{"date":294,"type":20},{"date":296,"type":20},{"name":37,"class":38},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":379,"minAge":63,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":396,"locationsCount":4},"100652466","age-of-puberty-onset-among-girls-in-asyut-egypt-100652466","NCT07773662","Age of Puberty Onset Among Girls in Asyut, Egypt","Age at Onset of Puberty Among Girls in Asyut Governorate, Egypt","Inclusion Criteria:\n\n* Girls aged 6-13 years showing progressive breast development.\n* Reside in Asyut governorate.\n* Parents\u002Fcaregivers agreed to provide informed consent (and child assent when appropriate).\n\nExclusion Criteria:\n\n* Premature thelarche.\n* Any pathological or iatrogenic factors that will be known by history.\n* Puberty due to central nervous system (CNS) lesions such as hypothalamic or pituitary tumor, hydrocephalus, etc.\n* Peripheral causes of puberty such as ovarian cyst or tumor, adrenal disorders, etc.\n* Endocrine disorders affecting puberty such as thyroid disorders or congenital adrenal hyperplasia.\n* Chronic systemic disease affecting puberty.\n* Current use of hormonal therapy.\n* Incomplete clinical data or refusal to participate in the study.","FEMALE","13 Years",{"count":382,"type":20},600,"Puberty is a critical transition from childhood to adulthood. Over the past two decades, studies worldwide have shown a trend toward earlier pubertal onset, which is thought to be influenced by factors such as lifestyle changes, improved nutrition, and environmental exposures. However, there is currently a lack of local data regarding the timing of puberty in Upper Egypt.\n\nThe main purpose of this observational study is to determine the average age at which puberty begins among girls living in the Asyut governorate, Egypt. The study specifically focuses on thelarche (breast development), which is the earliest clinical sign of pubertal onset. Additionally, the study aims to identify possible genetic, demographic, physical, and environmental factors that might influence the timing of this developmental milestone.\n\nThe study will include approximately 600 girls aged 6 to 13 years from both urban and rural areas of Asyut. Researchers will collect data during a single visit using a structured questionnaire administered through personal interviews with the participants and their parents or caregivers. The questionnaire will gather information on early life history, family history, dietary habits, physical activity, sleep patterns, screen time, stress, environmental exposures, and pubertal history. Researchers will also take basic physical measurements, including height, weight, and waist circumference to calculate Body Mass Index (BMI).\n\nParticipants will not be exposed to any invasive procedures or additional clinical risks beyond their routine care. The findings will help establish local reference values for pubertal development and support evidence-based adolescent health strategies in Egypt.",[385],"Puberty",[385,387,388,389,390,391,392],"Pubertal Onset","Thelarche","Menarche","Adolescent Health","Asyut","Egypt",{"date":28,"type":31},{"date":294,"type":20},{"date":296,"type":20},{"name":37,"class":38},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":404,"sex":379,"minAge":4,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":419,"locationsCount":135},"100651417","evaluation-of-fetal-heart-100651417","NCT07760194","Evaluation of Fetal Heart","Evaluation of Systolic and Diastolic Cardiac Functions in Fetuses With IUGR","Inclusion Criteria:\n\n* pregnant women\n* more than 28 weehs gestation\n\nExclusion Criteria:\n\n* intrauterine fetal death",true,{"count":406,"type":20},28,"Evaluation of fetal cardiac functions in cases complicated with growth restriction",[409],"Fetal Growth Restriction",[411,412,413],"Fetal heart","Echocardiography","IUGR","2026-08-12",{"date":416,"type":31},"2026-08-13",{"date":347,"type":20},{"date":294,"type":20},{"name":37,"class":38},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":16,"minAge":427,"maxAge":45,"enrollmentInfo":428,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":4},"100651377","self-care-education-for-joint-stiffness-and-functional-ability-in-rheumatoid-arthritis-100651377","NCT07761767","Self-Care Education for Joint Stiffness and Functional Ability in Rheumatoid Arthritis","Effectiveness of a Self-Care Educational Program on Joint Stiffness and Functional Ability in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* The criteria for selection were: patients\" age ranged between 20-65 years old; did not have any auditory, visual or psychological problems. Patients who are able to communicate and participate in the educational program.\n\nPatients who agree to participate in the study.\n\nExclusion Criteria:\n\n* Patients with severe cognitive or communication impairment. Patients with other severe musculoskeletal conditions that may affect functional ability.\n\nPatients who have participated in a similar self-care educational program recently.","20 Years",{"count":359,"type":20},[124],"Rheumatoid arthritis is a chronic inflammatory autoimmune disease that may cause joint stiffness, pain, reduced mobility, and impaired functional ability. Self-care education may help patients improve their knowledge and practices related to disease management, joint protection, physical activity, exercise, energy conservation, and symptom management.\n\nThis study aims to evaluate the effectiveness of a self-care educational program on joint stiffness and functional ability among patients with rheumatoid arthritis. Participants will be assigned to either a study group or a control group. The study group will receive the self-care educational program in addition to routine care, while the control group will receive routine care only. Joint stiffness and functional ability will be assessed before and after implementation of the educational program.",[432],"Rheumatoid Arthritis (RA)",[434,435,436,437],"Rheumatoid Arthritis","Self-Care","Joint Stiffness","Functional Ability",{"date":416,"type":31},{"date":131,"type":20},{"date":441,"type":20},"2027-04-01",{"name":37,"class":38},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":16,"minAge":450,"maxAge":64,"enrollmentInfo":451,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":453,"conditions":454,"keywords":458,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":468,"locationsCount":4},"100651762","recovery-trajectories-after-propofol-based-intravenous-anesthesia-in-toddlers-and-older-children-100651762","NCT07766629","Recovery Trajectories After Propofol-Based Intravenous Anesthesia in Toddlers and Older Children","Age-Stratified Recovery Trajectories Following Propofol-Based Total Intravenous Anesthesia: A Comparative Study Between Toddlers (3-6 Years) and Older Children (6-12 Years)","Inclusion Criteria:\n\n* Age 3-12 years\n* ASA I-II\n* Elective surgery under general anaesthesia\n* Surgical duration 30-120 minutes\n* Propofol TIVA as the primary anesthetic technique\n\nExclusion Criteria:\n\n* Neurological disorders\n* Developmental delay\n* Hepatic or renal impairment\n* Obesity (\\>95th percentile)\n* Concomitant sedative medications","3 Years",{"count":452,"type":20},64,"This observational study aims to compare how quickly and smoothly younger children (ages 3 to 6 years) recover from general anesthesia compared to older children (ages 6 to 12 years).\n\nWhile inhalational anesthesia (breathing in anesthetic gases) has traditionally been the standard for pediatric surgeries, total intravenous anesthesia (TIVA) using a short-acting medication called propofol is increasingly being used. Propofol TIVA offers several benefits, including reduced postoperative nausea and vomiting, less airway irritation, a smoother waking process, and an earlier readiness to go home. However, because children's bodies and metabolisms change rapidly as they grow, the way propofol is processed by and clears from the body varies significantly by age.\n\nCurrently, there is limited evidence detailing exactly how these age-related differences affect recovery times. To investigate this, researchers will monitor 64 children undergoing elective surgeries (lasting between 30 and 120 minutes) who receive propofol TIVA as their primary anesthetic.\n\nAfter the procedure, the study will measure the exact time it takes for participants in both age groups to meet specific, standardized safe-discharge criteria (known as Phase II recovery readiness). Researchers will also track several other important recovery factors, including the time it takes for children to open their eyes, pain levels, the occurrence of emergence delirium (agitation or confusion upon waking), and any breathing-related complications. By comparing the recovery trajectories of toddlers and older children, this research seeks to improve postoperative care planning and provide clearer expectations for pediatric intravenous anesthesia.",[455,456,457],"Anesthesia Recovery","Pediatric Anesthesia","Total Intravenous Anesthesia",[459,460,461,462,463],"Propofol","TIVA","Emergence Delirium","Postoperative Nausea and Vomiting","PAED Scale","2026-08-11",{"date":367,"type":31},{"date":294,"type":20},{"date":296,"type":20},{"name":37,"class":38},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":474,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":16,"minAge":476,"maxAge":4,"enrollmentInfo":477,"targetDuration":479,"studyType":67,"phases":4,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":4},"100651729","predictors-of-extubation-failure-in-ventilated-neonates-100651729","NCT07764575","Predictors of Extubation Failure in Ventilated Neonates","Neonates","Inclusion Criteria:\n\n* Neonates (gestational age 28-44 weeks corrected) mechanically ventilated for ≥48 hours\n* Planned extubation as determined by the treating neonatologist\n* Hemodynamically stable at enrollment\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Neuromuscular disorders\n* Thoracic malformations\n* Inborn error of metabolism\n* Unplanned\u002Faccidental extubation","1 Day",{"count":478,"type":20},124,"1 Year","This protocol proposes a prospective observational study to develop and validate such a model, directly addressing a critical evidence gap identified by recent systematic reviews.",[482,474,483],"Extubation Failure","NICU",{"date":367,"type":31},{"date":486,"type":20},"2026-12-01",{"date":488,"type":20},"2028-06-01",{"name":37,"class":38},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":21,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":504,"locationsCount":4},"100651665","phase-4-efficacy-of-ultrasound-guided-combined-greater-occipital-nerve-block-and-greater-auricular-nerve-block-versus-greater-occipital-nerve-block-alone-in-the-management-of-chronic-migraine-100651665","NCT07763678","Efficacy of Ultrasound-Guided Combined Greater Occipital Nerve Block and Greater Auricular Nerve Block Versus Greater Occipital Nerve Block Alone in the Management of Chronic Migraine","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of chronic migraine according to ICHD-3 criteria (1).\n* Patients free from major neurological or psychiatric disorders that may interfere with headache assessment or study participation (3,4).\n* Ability to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Medication-overuse headache according to ICHD-3 criteria .\n* Acute migraine medication use within 24 hours before intervention .\n* Previous trauma or surgery involving the occipital region .\n* Known hypersensitivity to local anesthetic agents.\n* Local skin infection, dermatological disease, or impaired occipital sensation at the injection site.\n* Bleeding diathesis, anticoagulan؛t therapy, or skull defect contraindicating peripheral nerve block .",{"count":497,"type":20},80,[23],"Migraine is one of the most prevalent neurological disorders worldwide and remains a leading cause of disability, particularly among individuals of working age. Chronic migraine affects approximately 1-2% of the global population and is associated with substantial impairment in quality of life, reduced work productivity, and increased healthcare utilization . Despite recent advances in migraine management, including calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and gepants, many patients continue to experience inadequate symptom control, treatment intolerance, or limited access to these therapies . Consequently, peripheral nerve blocks have emerged as effective non-pharmacological treatment options for patients with refractory migraine and other primary headache disorders .\n\nAmong the available interventional techniques, the greater occipital nerve block (GONB) is one of the most widely used procedures for both acute and preventive treatment of migraine. The therapeutic effect of GONB is believed to result from modulation of nociceptive transmission within the trigeminocervical complex, thereby reducing central sensitization and interrupting convergence between cervical and trigeminal afferents. Several randomized clinical trials and systematic reviews have demonstrated that GONB significantly reduces headache intensity, headache frequency, analgesic consumption, and migraine-related disability while maintaining an excellent safety profile .\n\nMigraine pain often involves overlapping sensory territories supplied by interconnected peripheral nerves. The greater auricular nerve (GAN), a superficial sensory branch of the cervical plexus arising from the C2 and C3 spinal nerves, supplies the skin over the parotid region, mastoid process, lower auricle, and angle of the mandible . Because cervical sensory afferents converge with trigeminal nociceptive pathways within the trigeminocervical complex, the GAN may contribute to peripheral nociceptive transmission involved in migraine pathophysiology . Combined blockade of multiple cervical sensory nerves may therefore provide broader interruption of peripheral nociceptive input, potentially enhancing analgesic efficacy and reducing central sensitization . Ultrasound-guided GONB has been shown to produce greater procedural accuracy and consistent clinical outcomes than landmark-guided techniques .\n\nDespite the increasing use of peripheral nerve blocks in headache medicine, evidence regarding the additional benefit of combining a greater auricular nerve block with the standard greater occipital nerve block remains limited. To the best of our knowledge, no prospective randomized double-blind clinical trial has directly compared ultrasound-guided combined GONB and GAN block with GONB alone in patients with chronic migraine.",[51],{"date":416,"type":31},{"date":294,"type":20},{"date":35,"type":20},{"name":37,"class":38},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":518,"locationsCount":4},"100651654","the-impact-of-tonsillectomy-techniques-on-secondary-tonsillectomy-bleeding-100651654","NCT07763704","The Impact of Tonsillectomy Techniques on Secondary Tonsillectomy Bleeding","Inclusion Criteria:\n\n* Secondary PTH (bleeding \\>24 hours post-tonsillectomy)\n* Tonsillectomy surgical technique: cold steel, bipolar diathermy, or Coblation\n* Any patient age (pediatric and adult patient are included)\n* Presenting to the AUH Emergency Department or ENT clinic\n\nInformed consent obtained (written parental consent + written child assent for patients under 18 years)\n\nExclusion Criteria:\n\n* Primary PTH (bleeding ≤24 hours post-op)\n* Tonsillectomy technique other than the three study techniques (e.g., laser, harmonic scalpel)\n* External approach tonsillectomy\n* Known bleeding disorder (pre-existing coagulopathy)\n* Concurrent head and neck malignancy\n* Refusal of informed consent",{"count":66,"type":20},"Post-tonsillectomy hemorrhage (PTH) is one of the most common and potentially life-threatening complications of tonsillectomy.\n\n* Secondary PTH (Bleeding occurring \\>24 hours post-operatively) is of particular clinical significance.\n* Tonsillectomy is a frequently performed procedure at Assiut University Hospital (AUH).\n* However, no local prospective data exists comparing secondary PTH rates across techniques, or systematically characterizing its causes.\n* This study addresses this gap by comparing rates, and analysis of causes.",[514],"Post-Tonsillectomy Bleeding",{"date":416,"type":31},{"date":294,"type":20},{"date":35,"type":20},{"name":37,"class":38},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":526,"targetDuration":4,"studyType":21,"phases":527,"briefSummary":528,"conditions":529,"keywords":531,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":535,"leadSponsor":536,"locationsCount":4},"100651549","phase-4-anti-inflammatory-effect-of-mgso-in-patients-with-moderate-traumatic-brain-injury-by-measurming-nucleotide-binding-oligomerization-domain-like-receptor-pyrin-domain-containing-3-nlrp3-inflammasome-a-multiprotein-complex-100651549","NCT07763665","Anti-inflammatory Effect of MgSO₄ in Patients With Moderate Traumatic Brain Injury by Measurming Nucleotide-binding Oligomerization Domain-Like Receptor Pyrin Domain-containing 3 (NLRP3) Inflammasome-a Multiprotein Complex","Anti-Inflammatory Effect of Magnesium Sulfate on the Outcomes of Patients With Moderate Traumatic Brain Injury.","Inclusion Criteria:\n\n1. Male and female patients aged 18 to 60 years.\n2. Sustained a closed head trauma with the study drug infusion initiated within 8 hours of the injury.\n3. TBI confirmed by history and clinical examination.\n4. Patients with moderate (GCS = 9-12) traumatic brain injury.\n5. Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (diffuse injury II-IV, evacuated and non-evacuated mass lesion, Marshall's CT Classification ).\n6. Hemodynamic stability at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patient Refusal\n2. Prolonged and\u002For uncorrectable hypoxia (PaO₂ \\\u003C 60 mmHg) or persistent hypotension (systolic blood pressure \\\u003C 90 mmHg) at the time of randomization.\n3. Cardiopulmonary arrest.\n4. Concomitant spinal cord injury.\n5. Pregnant or lactating females.\n6. Penetrating head injury.\n7. Associated other extra-cranial trauma or systemic polytrauma.\n8. Undergoing surgical interventions during the study.\n9. Pre-existing severe cardiac arrhythmia, heart block, or significant myocardial damage (documented on ECG).\n10. Known history of chronic renal failure or abnormal baseline renal function.\n11. Known hypersensitivity or allergic reaction to magnesium sulfate.\n12. Patients on chronic steroid therapy.\n13. BMI\\>35 kg\u002Fm2.\n\n    \\-",{"count":452,"type":20},[23],"The primary objective of this study is to evaluate the biochemical efficacy of Magnesium Sulfate (MgSO₄) as an anti-inflammatory therapeutic agent in patients suffering from moderate traumatic brain injury (TBI) at Assiut University Hospitals by measuring Nucleotide-binding oligomerization domain-Like Receptor Pyrin domain-containing 3 (NLRP3) inflammasome-a multiprotein complex.",[530],"Traumatic Brain Injuries",[532],"anti-inflammatory effect of magnesium sulfate",{"date":416,"type":31},{"date":222,"type":20},{"date":157,"type":20},{"name":37,"class":38},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":404,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":555,"locationsCount":4},"100651553","uromodulin-as-a-biomarker-in-lupus-nephritis-100651553","NCT07763834","Uromodulin as a Biomarker in Lupus Nephritis","Evaluation of Uromodulin as a Biomarker of Renal Histological Activity\u002F Chronicity Indices in Lupus Nephritis","Inclusion Criteria:\n\n* • Group I: 30 patients with different classes of Lupus Nephritis. These cases are biopsy proven\n\nLN. Histological diagnosis of LN is according to the revised International Society of\n\nNephrology\u002F Renal Pathology Society (ISN\u002FRPS) classification and modified National Institute of Health (NIH) activity and chronicity indices (Bajema et al 2018) .\n\n* Biopsy-proven lupus nephritis at the time of uromodulin blood sampling.\n* Group II: 10 patients with active SLE without renal involvement and with SLEDAI score ≥6\n* Group III: 10 patients with non-active SLE with SLEDAI score \\\u003C6\n* Group IV: 30 patients with primary forms of non-lupus Glomerulonephritis\n* Group V: 10 healthy control subjects\n* All cases are adults ≥18 years.\n* Diagnosis of systemic lupus erythematosus according to the 2019 EULAR\u002FACR Classification\n\nCriteria (Ref).Exclusion Criteria:\n\n* • .Pregnancy or lactation\n\n  * AKI secondary to pre renal OR post renal cause (from clinical history and imaging).\n  * End-stage renal disease requiring dialysis\n  * Active infection or sepsis\n  * Active malignancy (either under treatment or within 5 years of successful treatment)\n  * History of renal transplantation\n  * Heart failure with NYHA III and IV\n  * Hhistory of other autoimmune diseases or diabetes mellitus",{"count":545,"type":20},90,"Evaluation of Uromodulin as a biomarker of renal histological activity\u002F Chronicity indices in lupus nephritis",[548,549],"Uromodulin","SLE","2026-08-09",{"date":416,"type":31},{"date":222,"type":20},{"date":554,"type":20},"2030-03-03",{"name":37,"class":38},""]